MorphoSys AG (ETR:MOR) has received a consensus recommendation of “Hold” from the seven analysts that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is €119.86 ($139.37).
Several research firms recently weighed in on MOR. Royal Bank of Canada set a €130.00 ($151.16) price objective on shares of MorphoSys and gave the stock a “buy” rating in a research report on Tuesday, November 19th. HSBC set a €81.00 ($94.19) target price on shares of MorphoSys and gave the company a “sell” rating in a research report on Friday, August 16th. Goldman Sachs Group set a €114.00 ($132.56) price target on shares of MorphoSys and gave the stock a “neutral” rating in a research note on Tuesday, November 19th. Independent Research set a €110.00 ($127.91) price target on shares of MorphoSys and gave the stock a “neutral” rating in a report on Friday, November 1st. Finally, Berenberg Bank set a €145.00 ($168.60) price target on shares of MorphoSys and gave the stock a “buy” rating in a report on Wednesday, December 4th.
Shares of MOR opened at €120.40 ($140.00) on Monday. MorphoSys has a 12-month low of €79.70 ($92.67) and a 12-month high of €118.90 ($138.26). The company has a current ratio of 7.80, a quick ratio of 7.63 and a debt-to-equity ratio of 9.78. The company has a market cap of $3.80 billion and a PE ratio of -39.58. The stock has a 50-day moving average price of €102.88 and a 200-day moving average price of €99.16.
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Recommended Story: Back-End Load
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.